G Protein Coupled Receptors Market Analysis

The G-Protein Coupled Receptors Market size is projected to reach USD 3.9 Billion by 2032 at 7.1% CAGR during the forecast period 2023-2032. A rising need for glycoprotein-coupled receptors is expected to result from the increasing utilization of G-protein coupled receptors in pharmaceutical revelation and improvement forms.

The G-protein coupled receptors market is expected to be pushed by an increase in the incidence of cases of cancer, as well as an increase in the incidence of lifestyle-related diseases like cardiovascular diseases and respiratory ailments. G-protein coupled receptors market are extraordinarily beneficial to researchers for the development of novel pharmaceutical drugs. Additionally, it is projected that increased government support for research and development programs in clinical development would contribute to the market's expansion. Aside from that, the operational and structural study on the pharmacological components of GPCRs reveals the adaptive use of GPCR targets in the treatment of a diverse range of illnesses, which is assisting the G-protein coupled receptors market in its expansion. The high expense associated with maintaining GPCR cell lines is a significant impediment to expanding the G-protein coupled receptors (GPCR) business.

This report contains all the information on the global G-Protein Coupled Receptors Market analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global G-Protein Coupled Receptors Market forecast for 2027 is also included in the report.

Covid 19 Analysis

It has been shown that GPR4 plays an essential role in the pathophysiology of Covid-19 and might be used as a potential treatment target for curing Covid-19 infected patients, depending on the clinical signs of coronavirus-infected individuals. Covid-19-induced hyper-permeability of blood vessels, hyper-inflammatory responses, exudate production, pulmonary edoema, vascular thrombosis, and tissue damage may all be mitigated by using this treatment method.

In February 2024, Cumulus Oncology, a biotech company, announced the establishment of GIO Therapeutics AG in Basel, Switzerland. This recently founded biotechnology business specializes in the advancement of medications that specifically target G protein-coupled receptors (GPCR). GIO Therapeutics is the second firm to be created under Cumulus Oncology's company formation model. The judicious allocation of resources allows the organization to prioritize prospects that have robust scientific validation and a viable path for commercialization. Consequently, this enables the organization to concentrate on enhancing treatment results for patient populations with restricted therapy alternatives. Cumulus has successfully obtained pre-seed financing in 2020 and has since been focused on refining a financially effective company plan. The company acquires innovative cancer assets from academic institutes, commercial drug discovery groups, and biopharmaceutical companies.

Drivers

The growing number of medications now being tested in clinical and preclinical trials that address these receptors is encouraging. In 2018, around 19 percent of medications in clinical trial phase 1 targeted G protein-coupled receptors, according to the most recent available data. There is a wide range of agents available that boost GPCR activity. Salmeterol and albuterol are beta-adrenergic GPCR agonists that attach and activate beta-adrenergic GPCRs in the lungs, stimulating airway relaxation. They are used to treat several respiratory disorders, including chronic bronchitis and asthma.

Opportunities

The increasing utilization of G-protein coupled receptors in the disclosure and development of pharmaceutical products. Allosteric modulators, biological medicines, and biassed agonists are being developed to achieve these receptors in rising numbers. There are a vast number of FDA-approved medications that target G-protein coupled receptors on the market today. As of 2018, around 700 medicines targeting G protein-coupled receptors have been authorized by the Food and Drug Administration (GPCRs).

Restraints

The high prices linked with G-protein coupled receptors cell lines, on the other hand, would function as a significant growth restriction in the market. Unfavorable reimbursement rules, particularly in developing countries, will offer further obstacles to the G-Protein Coupled Receptors Market growth. 

Challenges

The scarcity of competent individuals or certified expertise may further hinder the market's development pace in the future. Stringent laws and standards governing the authorization procedure will also impede the sector's expansion.

Cumulative Growth Analysis

Due to significant expenditures in cancer research, the authorization of GPCR-targeted medications, and an increasing emphasis on pharmaceutical research, North America dominated the worldwide G-protein coupled receptors market in 2018. According to the FDA, there were 134 GPCR targets licensed in the US or EU in November 2017, and 128 targets were included in the FDA orange book at that time. There are various rising firms in the Asia Pacific area, such as HD Biosciences Co., Ltd., Sosei Heptares, and NB Health Laboratory, all of which have high growth prospects in the following years. Geographical growth is fueled by the amount of enterprises' efforts to appeal to a broader.

Value Chain Analysis

According to the reports, the global G-Protein Coupled Receptors Market is segmented based on product, assay type, application, and regions. The widest choice of cell lines for assays led to the highest overall revenue of cell lines in 2018. Cell lines are essential in cellular impedance tests for GPCR target identification, contributing to the expected revenue share. Detection kits have gained significant popularity because of their ease of use, robustness, and high sensitivity. Proposed detection tactics based upon nonlabelled systems, such as resonant waveguide grating or impedance-based sensors, could also help the market flourish.

Because cAMP is an essential intracellular 2nd messenger in GPCR signal transduction, cAMP assays commanded the highest profit share in 2018. The market is driven by an extensive product array of test kits for measuring cAMP mediator levels. Using calcium flux assays has several benefits, including excellent specificity, simplicity of estimating calcium flow, and user configurability.

G-Protein Coupled ReceptorsSegment Insights

The market is segmented based on product, assay type, application, and regions. The global G-Protein Coupled Receptors Market trends are expected to witness decent growth during the forecast period.

G-Protein Coupled Receptors Application Insights

Based on the Application, the market is segmented into Cardiovascular systems, Oncology, Immunology, Respiratory systems, Central Nervous systems, and Others.

G-Protein Coupled Receptors End-Users Insights

Based on the propulsion types, the market is segmented into Cell Lines, Detection Kits, Cell Culture Reagents, and Ligands.

G-Protein Coupled Receptors Regional Insights

According to the reports, based on the region, the global G-Protein Coupled Receptors Market is divided into America, Europe, Asia Pacific, and the middle east and Africa. Americas is the biggest market for G protein-coupled receptors because of the significant expenditures in disease research that drive the industry's expansion.

The European G protein-coupled receptors market share is expected to see increased demand as more medications targeting GPCRs is licensed for use. European Union approval of 134 GPCR sites for medicines in November 2017 and FDA orange book listing of 128 GPCR targets fueled the expansion of the G protein-coupled receptors industry in this area in the year.

The fastest-growing region in the Asia-Pacific region. Due to the advent of various new businesses, including HD Biosciences Co. Ltd. and NB Health Laboratory, this area is becoming more competitive. For the G protein-coupled receptor in this area to grow, more and more firms are taking steps to expand their market position. G-protein coupled receptors market outlook are in high need in the Middle East and Africa due to increased healthcare costs and public funding.

Competitive landscape

The government's funding for research and development efforts in the market for G-protein coupled receptors market value is increasing. The federal government is funding research and innovation for biosensors, sedate targets, orphan drug receptors, and high-throughput screening technologies to attach the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as for other applications (GDP).

G-Protein Coupled Receptors Market Major Key Players

• Thermo Fisher Scientific, Inc. (US)


• Abcam PLC (UK)


• QIAGEN (Germany)


• Promega Corporation (US)


• PerkinElmer Inc. (US)


• Enzo Life Sciences, Inc. (US)


• BD (US)


• Cisbio (Europe)


• Merck Group (Germany)


• HD Biosciences Co., Ltd (China)

Report Overview

The following report comprises of –

• Market overview 


• Covid 19 Analysis


• Market Dynamic


• Drivers


• Opportunities


• Restraints 


• Challenges


• Cumulative Growth Analysis


• Value Chain Analysis


• Segmentation Overview 


• By Application 


• By End-Users


• Regional Analysis


• Competitive landscape

Recent Developments